US20120177691A1 - Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit - Google Patents

Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit Download PDF

Info

Publication number
US20120177691A1
US20120177691A1 US13/383,822 US201013383822A US2012177691A1 US 20120177691 A1 US20120177691 A1 US 20120177691A1 US 201013383822 A US201013383822 A US 201013383822A US 2012177691 A1 US2012177691 A1 US 2012177691A1
Authority
US
United States
Prior art keywords
composition
fucosyllactose
oligosaccharides
human
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/383,822
Other languages
English (en)
Inventor
Bernd Stahl
Alma Jildou Nauta
Johan Garssen
Eric Samain
Sophie Drouillard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutricia NV
Original Assignee
Nutricia NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41016877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20120177691(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutricia NV filed Critical Nutricia NV
Priority to US13/383,822 priority Critical patent/US20120177691A1/en
Assigned to N.V. NUTRICIA reassignment N.V. NUTRICIA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DROUILLARD, SOPHIE, GARSSEN, JOHAN, NAUTA, ALMA JILDOU, SAMAIN, ERIC, STAHL, BERND
Publication of US20120177691A1 publication Critical patent/US20120177691A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Definitions

  • the present invention relates to infant nutrition with non-digestible oligosaccharides, in particular to the use thereof for stimulating the immune system.
  • Human milk fed infants have a lower incidence of infections, including viral infections, than formula fed infants.
  • Many components in human milk including immunoglobulins (such as IgA), interleukin (IL)-1, IL-6, IL-8, IL-10, interferon- ⁇ (IFN- ⁇ ), immunocompetent cells, transforming growth factor-13 (TGF-13), lactoferrin, nucleotides, and non-digestible oligosaccharides (NDO) are thought to be involved in protection against infection with enteric or respiratory pathogens.
  • TGF- ⁇ and dietary nucleotides were found to be components which may be responsible for increase in natural killer cell activity.
  • NDO are a major constituent of human milk and are a major element of the innate immune system of human milk. Human NDO promote the growth of a beneficial microbiota dominated by bifidobacteria and lactobacilli. Some human NDO are also known to be able to prevent directly the adhesion of pathogens and toxins.
  • Human milk is the preferred food for infants. However, it is not always possible or desirable to breast feed an infant. In such cases infant formulae or follow on formulae are a good alternative. These formulae should have an optimal composition in order to mimic the beneficial effects of breast milk as close as possible.
  • WO 2007/067053 discloses infant formula comprising the plant-derived prebiotics inulin and galacturonic acid oligosaccharide and the from lactose synthesized prebiotic transgalacto-oligosaccharide to reduce infections.
  • WO 2007/010084 discloses mannan-poly- and oligosaccharides for immune stimulation.
  • the carbohydrate mixture is said to have both a nutritional and a biological effect which is considerably greater than the corresponding action of the individual constituents.
  • EP 1 629 850 provides a method and composition for the treatment and/or prevention of respiratory tract infection and/or respiratory tract infection disease, said method comprising orally administering a composition to a mammal, said composition comprising a galactose containing indigestible oligosaccharide and at least 5 wt.% digestible galactose saccharide.
  • EP 2 072 052 relates to a composition suitable for use in the prevention of opportunistic infections in immune-compromised individuals comprising a probiotic and a fucosylated oligosaccharide selected from the group comprising 2′-fucosyllactose, 3′fucosyllactose, difucosyllactose, lacto-N-fucopentaose, lacto-N-fucohexaose, fucosyllacto-N-hexaose and fucosyllacto-N-neohexaose.
  • the document further discloses the use of such a composition in the prevention of opportunistic infections in immune-compromised individuals.
  • Human milk differs from milk from domestic animals in that it comprises more NDO and in that the NDO are structurally different.
  • the group of human NDO is very complex, since it represents a heterogenic group of more than 130 different compounds with diverse sugar composition. Because of their complex and polymorphic structure, large-scale synthesis is complicated. It is therefore not yet technically and economically feasible to prepare infant nutrition with an NDO composition identical to human milk.
  • FL fucosyllactose
  • NK Natural Killer
  • the present invention thus concerns a method for stimulating NK cell activity and/or NK cell proliferation in a subject, said method comprising administering a composition comprising fucosyllactose to said subject, said composition not being human milk.
  • the present method is a non-medical method for stimulating NK cell activity and/or NK cell proliferation in a subject.
  • the present method is for treating and/or preventing viral infections in a subject.
  • the present invention also concerns a method for treating and/or preventing viral infections in a subject, said method comprising administering a composition comprising fucosyllactose to said subject, said composition not being human milk.
  • the invention can also be worded as the use of fucosyllactose in the manufacture of a composition for stimulating NK cell activity and/or NK cell proliferation, said composition not being human milk.
  • the composition is for treating and/or preventing viral infections.
  • the invention can also be worded as the use of fucosyllactose in the manufacture of a composition for treating and/or preventing viral infections, said composition not being human milk.
  • the invention can also be worded as a composition comprising fucosyllactose for stimulating, in particular for use in stimulating, NK cell activity and/or NK cell proliferation, said composition not being human milk.
  • the composition is for use in treating and/or preventing, viral infections.
  • the invention can also be worded as a composition comprising fucosyllactose for treating and/or preventing, in particular for use in treating and/or preventing, viral infections, said composition not being human milk.
  • the invention also concerns a method for treating and/or preventing infections, by stimulating natural killer (NK) cell activity and/or NK cell proliferation, said method comprising administering a composition comprising fucosyllactose to said subject, said composition not being human milk.
  • NK natural killer
  • the invention can also be worded as the use of fucosyllactose in the manufacture of an enteral composition for treating and/or preventing infections, by stimulating natural killer (NK) cell activity and/or NK cell proliferation, said composition not being human milk.
  • NK natural killer
  • the invention can also be worded as a composition comprising fucosyllactose for treating and/or preventing infections, in particular for use in and/or preventing infections, by stimulating natural killer (NK) cell activity and/or NK cell proliferation, said composition not being human milk.
  • NK natural killer
  • the invention also concerns a method for enhancing vaccination response, said method comprising administering a composition comprising fucosyllactose to said subject, said composition not being human milk.
  • the method is for enhancing vaccination response to vaccination with viral antigens.
  • the invention can also be worded as the use of fucosyllactose in the manufacture of an enteral composition for enhancing vaccination response.
  • the composition is for enhancing vaccination response to vaccination with viral antigens.
  • the invention can also be worded as a composition comprising fucosyllactose for enhancing, in particular for use in enhancing, vaccination response.
  • the composition is for enhancing vaccination response to vaccination with viral antigens.
  • composition that is administered according to the present method, or that is used according to the present invention is preferably enterally administered, more preferably orally.
  • the composition is preferably for enteral, preferably oral administration or in other words the composition is an enteral, preferably oral, composition.
  • the present composition comprises fucosyllactose.
  • Fucosyllactose FL is a non-digestible oligosaccharide present in human milk. It is not present in bovine milk. It consists of three monose units, fucose, galactose and glucose linked together. Galactose linked to glucose via a beta 1 ⁇ 4 linkage is called lactose.
  • a fucose unit is linked to a galactose unit of a lactose via an alpha 1,2 linkage (2′-fucosyllactose, 2′-FL) or to the glucose unit of lactose via an alpha 1,3 linkage (3-fucosyllactose, 3-FL).
  • the present composition preferably comprises 2′-FL.
  • 2′-FL preferably ⁇ -L-Fuc-(1 ⁇ 2)- ⁇ -D-Gal-(1 ⁇ 4)-D-Glc, and 3-FL, preferably ⁇ -L-Fuc-(1 ⁇ 3)-[ ⁇ -D-Gal-(1 ⁇ 4)]-D-Glc
  • 3-FL preferably ⁇ -L-Fuc-(1 ⁇ 3)-[ ⁇ -D-Gal-(1 ⁇ 4)]-D-Glc
  • the composition comprises 1 mg to 3 g fucosyllactose per 100 ml, more preferably 10 mg to 2 g, even more preferably 20 mg to 100 mg FL per 100 ml.
  • the composition preferably comprises 0.007 wt % to 20 wt % fucosyllactose, more preferably 0.07 wt % to 10 wt %, even more preferably 0.15 wt % to 1 wt %.
  • a lower amount of fucosyllactose will be less effective in increasing NK cells and/or increasing NK cell activity, whereas a too high amount will result in unnecessary high costs of the product.
  • the present composition preferably comprises non-digestible oligosaccharides (NDO) other than FL.
  • NDO non-digestible oligosaccharides
  • the NDO other than FL stimulate the growth of bifidobacteria and/or lactobacilli, more preferably bifidobacteria.
  • An increased content of bifidobacteria and/or lactobacilli stimulate the formation of a healthy intestinal microbiota.
  • the NDO are preferably not or only partially digested in the intestine by the action of acids or digestive enzymes present in the human upper digestive tract, in particular in the small intestine and stomach, and are fermented by the human intestinal microbiota.
  • sucrose, lactose, maltose and the common maltodextrins are considered digestible.
  • the present composition comprises non-digestible oligosaccharides with a DP in the range of 2 to 250, more preferably 2 to 60.
  • the non-digestible oligosaccharide is preferably at least one, more preferably at least two, preferably at least three selected from the group consisting of fructo-oligosaccharides, galacto-oligosaccharides, xylo-oligosaccharides, arabino-oligosaccharides, arabinogalacto-oligosaccharides, gluco-oligosaccharides, chito-oligosaccharides, glucomanno-oligosaccharides, galactomanno-oligosaccharides, mannan-oligosaccharides, sialic acid comprising oligosaccharides, and uronic acid oligosaccharides.
  • the group of fructo-oligosaccharides includes inulins
  • the group of galacto-oligosaccharides includes transgalacto-oligosaccharides or beta-galacto-oligosaccharides
  • the group of gluco-oligosaccharides includes cyclodextrins, gentio- and nigero-oligosaccharides and non-digestible polydextrose
  • the group of galactomanno-oligosaccharides includes partially hydrolyzed guar gum
  • the group of uronic acid oligosaccharides includes galacturonic acid oligosaccharides and pectin degradation products.
  • the present composition comprises at least one, more preferably at least two, most preferably three selected from the group consisting of fructo-oligosaccharides, beta-galacto-oligosaccharides and uronic acid oligosaccharides. More preferably the composition comprises beta-galacto-oligosaccharides.
  • the composition comprises a mixture of inulin and short chain fructo-oligosaccharides.
  • the composition comprises a mixture of galacto-oligosaccharides and fructo-oligosaccharides selected from the group consisting of short chain fructo-oligosaccharides and inulin, more preferably inulin.
  • a mixture of at least two different non-digestible oligosaccharides advantageously stimulates the beneficial bacteria of the intestinal microbiota to a greater extent.
  • the weight ratio in a mixture of the two different non-digestible oligosaccharides, preferably galacto-oligosaccharides and fructo-oligosaccharide is between 25 and 0.05, more preferably between 20 and 1.
  • Galacto-oligosaccharides, preferably beta-galacto-oligosaccharides are more capable of stimulating bifidobacteria.
  • the present composition comprises galacto-oligosaccharides, preferably beta-galacto-oligosaccharides, with a degree of polymerization (DP) of 2 to 10 and/or fructo-oligosaccharides with a DP of 2 to 60.
  • DP degree of polymerization
  • the galacto-oligosaccharides preferably are beta-galacto-oligosaccharides.
  • the present composition comprises beta-galacto-oligosaccharides ([galactose]n-glucose; wherein n is an integer ranging from 2 to 60, i.e. 2, 3, 4, 5, 6, . . . . , 59, 60; preferably n is selected from 2, 3, 4, 5, 6, 7, 8, 9, and 10), wherein the galactose units are in majority linked together via a beta linkage.
  • Beta-galacto-oligosaccharides are also referred to as trans-galacto-oligosaccharides (TOS).
  • Beta-galacto-oligosaccharides are for example sold under the trademark VivinalTM (Borculo Domo Ingredients, Netherlands). Another suitable source is Bi2Munno (Classado).
  • the TOS comprises at least 80% beta-1,4 and beta-1,6 linkages based on total linkages, more preferably at least 90%.
  • Fructo-oligosaccharide is a NDO comprising a chain of beta-linked fructose units with a DP or average DP of 2 to 250, more preferably 2 to 100, even more preferably 10 to 60.
  • Fructo-oligosaccharide includes inulin, levan and/or a mixed type of polyfructan.
  • An especially preferred fructo-oligosaccharide is inulin.
  • Fructo-oligosaccharide suitable for use in the compositions is also commercially available, e.g. Raftiline®HP (Orafti).
  • the fructo-oligosaccharide has an average DP above 20.
  • Uronic acid oligosaccharides are preferably obtained from pectin degradation products.
  • the present composition preferably comprises a pectin degradation product with a DP of 2 to 100.
  • the pectin degradation product is prepared from apple pectin, beet pectin and/or citrus pectin.
  • the uronic acid oligosaccharide is a galacturonic acid oligosaccharide.
  • the composition comprises FL and one of the group selected from galacto-oligosaccharide and uronic acid oligosaccharide.
  • the composition comprises beta-galacto-oligosaccharide, fructo-oligosaccharide and a uronic acid oligosaccharide. It was found that such a combination acts synergistically with fucosyllactose, in particular 2′-fucosyllactose.
  • the weight ratio beta-galacto-oligosaccharide:fructo-oligosaccharide:uronic acid oligosaccharide is preferably (20 to 2):1:(1 to 20), more preferably (20 to 2):1:(1 to 10), even more preferably (20 to 2):1:(1 to 3), even more preferably (12 to 7):1:(1 to 2). Most preferably the weight ratio is about 9:1:1.1.
  • the weight ratio FL to beta-galacto-oligosaccharide is from 5 to 0.05, more preferably 5 to 0.1, more preferably from 2 to 0.1.
  • the weight ratio FL to fructo-oligosaccharide, preferably inulin is from 10 to 0. 05, more preferably 10 to 0.1, more preferably from 2 to 0.5.
  • the weight ratio FL to uronic acid oligosaccharide, preferably derived from pectin is from 10 to 0. 05, more preferably 10 to 0.1 more preferably from 2 to 0.5.
  • the composition comprises 80 mg to 4 g non-digestible oligosaccharides, including fucosyllactose, per 100 ml, more preferably 150 mg to 2 g, even more preferably 300 mg to 1 g non-digestible oligosaccharides per 100 ml.
  • the composition preferably comprises 0.25 wt % to 25 wt % non-digestible oligosaccharides including fucosyllactose, more preferably 0.5 wt % to 10 wt %, even more preferably 1.5 wt % to 7.5 wt %.
  • a lower amount of non-digestible oligosaccharides will be less effective in stimulating the beneficial bacteria in the microbiota, whereas a too high amount will result in side-effects of bloating and abdominal discomfort.
  • the composition comprising fucosyllactose is a nutritional composition.
  • the composition of the present invention is not human milk.
  • the present composition is preferably enterally administered, more preferably orally.
  • the present composition is preferably a nutritional formula, preferably an infant formula.
  • the present composition can be advantageously applied as a complete nutrition for infants.
  • the present composition preferably comprises a lipid component, protein component and carbohydrate component and is preferably administered in liquid form.
  • the present invention includes dry food, preferably a powder, which is accompanied with instructions as to admix said dry food mixture with a suitable liquid, preferably with water.
  • the present invention advantageously provides a composition wherein the lipid component provides 5 to 50% of the total calories, the protein component provides 5 to 50% of the total calories, and the digestible carbohydrate component provides 15 to 85% of the total calories.
  • the present invention advantageously provides a composition wherein the lipid component provides 20 to 50% of the total calories, the protein component provides 5 to 30% of the total calories, and the digestible carbohydrate component provides 30 to 70% of the total calories.
  • the lipid component provides 35 to 50% of the total calories
  • the protein component provides 7.5 to 12.5% of the total calories
  • the digestible carbohydrate component provides 40 to 55% of the total calories.
  • the total of energy provided by the proteins, peptides and amino acids needs to be taken into account.
  • the present composition preferably comprises at least one lipid selected from the group consisting of animal lipid, excluding human lipids, and vegetable lipids.
  • the present composition comprises a combination of vegetable lipids and at least one oil selected from the group consisting of fish oil, animal oil, algae oil, fungal oil, and bacterial oil.
  • the present composition preferably comprises long chain poly-unsaturated fatty acids (LC-PUFA).
  • LC-PUFA are fatty acids or fatty acyl chains with a length of 20 to 24 carbon atoms, preferably 20 or 22 carbon atoms comprising two or more unsaturated bonds.
  • the present composition comprises eicosapentaenoic acid (EPA, n-3), docosahexaenoic acid (DHA, n-3) and/or arachidonic acid (ARA, n-6).
  • the present composition comprises at least 0.1 wt.%, preferably at least 0.25 wt.%, more preferably at least 0.6 wt.%, even more preferably at least 0.75 wt.% LC-PUFA with 20 and 22 carbon atoms based on total fat content.
  • the content of LC-PUFA particularly the LC-PUFA with 20 and 22 carbon atoms, preferably does not exceed 6 wt %, more preferably does not exceed 3 wt.% of the total fat content as it is desirable to mimic human milk as closely as possible.
  • the LC-PUFA may be provided as free fatty acids, in triglyceride form, in diglyceride form, in monoglyceride form, in phospholipid form, or as a mixture of one of more of the above.
  • the present composition preferably comprises between 5 and 75 wt.% polyunsaturated fatty acids based on total fat, preferably between 10 and 50 wt.%.
  • the protein used in the nutritional composition is preferably selected from the group consisting of non-human animal proteins (preferably milk proteins), vegetable proteins (preferably soy protein and/or rice protein), hydrolysates thereof, free amino acids and mixtures thereof.
  • the present composition preferably contains casein, whey, hydrolyzed casein and/or hydrolyzed whey protein.
  • the protein comprises intact proteins, more preferably intact bovine whey proteins and/or intact bovine casein proteins.
  • the present composition preferably contains digestible carbohydrates selected from the group consisting of sucrose, lactose, glucose, fructose, corn syrup solids, starch and maltodextrins, more preferably lactose.
  • the liquid food does not have an excessive caloric density, however still provides sufficient calories to feed the subject.
  • the liquid food preferably has a caloric density between 0.1 and 2.5 kcal/ml, even more preferably a caloric density of between 0.5 and 1.5 kcal/ml, most preferably between 0.6 and 0.8 kcal/ml.
  • the present composition comprises nucleotides and/or nucleosides, more preferably nucleotides.
  • the composition comprises cytidine 5′-monophospate, uridine 5′-monophospate, adenosine 5′-monophospate, guanosine 5′-monophospate, and/or inosine 5′-monophospate, more preferably cytidine 5′-monophospate, uridine 5′-monophospate, adenosine 5′-monophospate, guanosine 5′-monophospate, and inosine 5′-monophospate.
  • the composition comprises 5 to 100, more preferably 5 to 50 mg, most preferably 10 to 50 mg nucleotides and/or nucleosides per 100 gram dry weight of the composition.
  • the presence of nucleotides and/or nucleotides advantageously stimulates NK cell activity.
  • the nucleotides and/or nucleosides are deemed to act synergistically with the fucosyllactose of the present composition.
  • the present composition is used for stimulating natural killer cell activity and/or natural killer cell proliferation. In one embodiment the present composition is used for treating and/or preventing viral infections. In one embodiment the composition for stimulating natural killer cell activity and/or natural killer cell proliferation, and/or for treating and/or preventing viral infections is for administering to HIV patients, elderly and/or oncology patients.
  • NK cells are a type of cytotoxic lymphocytes that constitute a major component of the innate immune system. NK cells play a major role in defense against intracellular infections. NK-cells are defined as large granular lymphocytes that do not express T-cell antigen receptors (TCR) or Pan T marker CD3 or surface immunoglobulins (Ig) B cell receptor but that usually express the surface markers CD16 (Fc ⁇ RIII) and CD56 in humans. They were named “natural killers” because of the initial notion that they do not require activation in order to kill cells that are missing “self' markers of major histocompatibility complex (MHC) class I. NK cells have two major types of effector function; cell killing and the secretion of cytokines.
  • TCR T-cell antigen receptors
  • Ig surface immunoglobulins
  • a nutritional composition comprising fucosyllactose is therefore preferably for preventing and/or treating viral infections, more preferably viral infections caused by orthomyxoviridae, in particular the influenza virus, herpesviridae, rotavirus, cytomegalovirus, caliciviridae, respiratory syncytial virus, human imunodeficiency virus and/or rhinovirus.
  • a nutritional composition comprising fucosyllactose is therefore preferably for preventing and/or treating viral infections, more preferably the viral infections common cold, flu, measles, chicken pox, viral diarrhoea, viral gastro-enteritis, HIV infection and/or viral respiratory tract infections.
  • the present invention is used for HIV patients.
  • the present invention concerns providing nutrition to a HIV patient.
  • the present composition is advantageous for HIV patients since HIV patients have a decreased natural killer cell activity.
  • the use of a nutritional composition comprising fucosyllactose is therefore especially beneficial for infant formula.
  • the present invention concerns providing nutrition to an infant.
  • Formula fed infants have an underdeveloped immune system compared with adults and are more prone to viral infections than human milk fed infants.
  • the infant is from 0 to 36 months of age, more preferably of 0 to 18 months, even more preferably of 0 to 12 months, most preferably of 0 to 6 months of age. The younger the infant is, the less developed the immune system.
  • composition comprising fucosyllactose even more advantageously is used in preterm infants and/or very low or low birth weight infants, since these infants are even more vulnerable and/or prone to viral infections.
  • composition comprising fucosyllactose even more advantageously is used in infants delivered via Caesarean section.
  • Caesarean section born infants are born in a hospital in an environment having more pathogens against which the antibodies, conferred by the mother to the infant, are not effective against.
  • Caesarean section born infants have a delayed and less optimal colonization of the large intestinal tract and therefore are also more prone to intestinal infections.
  • the composition comprising fucosyllactose is advantageously used for nutrition for elderly.
  • the present invention concerns providing nutrition to an elderly person.
  • An elderly person is a person having an age of 55 years or more, in particular of the age of 65 or more.
  • Elderly have a demonstrated lower activity of natural killer cell activity than healthy young adult individuals.
  • Elderly are especially vulnerable to viral infection complications.
  • the present invention is used for treatment and/or prevention of immunosenescence in elderly. Elderly are more prone to the development of tumours.
  • NK cell activity suppresses tumour cell proliferation.
  • the present invention is used for nutrition in cancer patients. Oncology patients have a lower natural killer cell activity than healthy young adult individuals.
  • Vaccination experiments were performed using Influvac (Solvay Pharmaceuticals, Weesp, the Netherlands) from season 2005/2006.
  • the mice received a primary vaccination and a booster vaccination, consisting of a subcutaneous (sc) injection of a 1:1 mix of vaccine and adjuvant in a total volume of 100 ⁇ l.
  • the booster vaccination was given at 21 days after the primary vaccination.
  • the experiments ended 10 days after booster vaccination. Blood samples were taken at the end of the experiment.
  • Negative control groups that were included received injections with a 1:1 mix of PBS and adjuvant in a total volume of 100 ⁇ l.
  • To determine the percentage of NK cells cells were labelled with FITC-labelled anti-mouse CD3 mAb in combination with PE-labelled anti-mouse NK1.1 mAb.
  • the percentage of regulatory T cells was determined by flow cytometry (FACSCalibur) using allophycocyanin (APC-)labelled anti-mouse CD3 mAb, Pe-Cy5-labeled anti-mouse CD4 mAb and phycoerythrin (PE)-labelled anti-mouse CD25 mAb in combination with intracellular staining of fluorescein-isotiocyanate (FITC)-labelled Foxp3 mAb, according to the instructions offered by the manufactures (Biosciences, San Diego, Calif.).
  • NK cell activity was measured in mouse splenocytes. A significant increased NK cell activity was detected in the splenocytes of mice that were supplemented with 2′-FL compared to controls, see Table 1.
  • the decrease in regulatory T cells is indicative for a decreased inhibition of immune response and hence enables an increased vaccination response to the viral antigens.
  • a temporarily decrease of regulatory T cells can be especially beneficial when vaccination is to occur.
  • results support that oral supplementation with 2′-FL stimulates growth and/or activity of NK cells. These results are indicative for an effect of dietary 2′-FL for enhancing vaccination response, in particular vaccination with viral antigens. These results are indicative for an effect of dietary 2′-FL for treating and/or preventing viral infections.
  • Infant formula for stimulating NK cell activity comprising per 100 ml (13.9 dry weight):
  • non-digestible oligosaccharides of which 80 mg 2′-fucosyllactose and 640 mg beta-galacto-oligosaccharides, and 80 mg fructo-oligosaccharides
  • choline choline, myo-inositol, taurine, minerals, trace elements, and vitamins as known in the art.
  • a preferred composition that can be used for the stimulation of natural killer cell activity in HIV patients may comprise per 100 g dry weight.
US13/383,822 2009-07-15 2010-07-12 Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit Abandoned US20120177691A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/383,822 US20120177691A1 (en) 2009-07-15 2010-07-12 Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09165485 2009-07-15
EP09165485.5 2009-07-15
US25645309P 2009-10-30 2009-10-30
PCT/NL2010/050447 WO2011008087A1 (en) 2009-07-15 2010-07-12 Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
US13/383,822 US20120177691A1 (en) 2009-07-15 2010-07-12 Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2010/050447 A-371-Of-International WO2011008087A1 (en) 2009-07-15 2010-07-12 Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/869,436 Continuation US20160158346A1 (en) 2009-07-15 2015-09-29 Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit

Publications (1)

Publication Number Publication Date
US20120177691A1 true US20120177691A1 (en) 2012-07-12

Family

ID=41016877

Family Applications (5)

Application Number Title Priority Date Filing Date
US13/383,822 Abandoned US20120177691A1 (en) 2009-07-15 2010-07-12 Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
US14/869,436 Abandoned US20160158346A1 (en) 2009-07-15 2015-09-29 Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
US15/866,667 Active US10588965B2 (en) 2009-07-15 2018-01-10 Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
US16/750,565 Active US11135290B2 (en) 2009-07-15 2020-01-23 Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
US17/493,647 Pending US20220023418A1 (en) 2009-07-15 2021-10-04 Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit

Family Applications After (4)

Application Number Title Priority Date Filing Date
US14/869,436 Abandoned US20160158346A1 (en) 2009-07-15 2015-09-29 Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
US15/866,667 Active US10588965B2 (en) 2009-07-15 2018-01-10 Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
US16/750,565 Active US11135290B2 (en) 2009-07-15 2020-01-23 Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
US17/493,647 Pending US20220023418A1 (en) 2009-07-15 2021-10-04 Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit

Country Status (9)

Country Link
US (5) US20120177691A1 (de)
EP (4) EP4197542A1 (de)
CN (1) CN102497869B (de)
BR (1) BR112012000859B1 (de)
ES (2) ES2525565T3 (de)
MY (2) MY164674A (de)
PL (2) PL3342413T3 (de)
RU (1) RU2530641C2 (de)
WO (1) WO2011008087A1 (de)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150031645A1 (en) * 2010-12-31 2015-01-29 Abbott Laboratories Methods of using human milk oligosaccharides for improving airway respiratory health
WO2016139328A1 (en) * 2015-03-05 2016-09-09 Nestec S.A. Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children
US9539269B2 (en) 2010-12-31 2017-01-10 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
US9763970B2 (en) 2010-12-31 2017-09-19 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
US9808474B2 (en) 2010-12-31 2017-11-07 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US20190209593A1 (en) * 2016-09-07 2019-07-11 Nestec S.A. Nutritional compositions for infants and/or young children comprising oligosaccharides
US10420784B2 (en) 2009-07-15 2019-09-24 N.V. Nutricia Mixture of non-digestible oligosaccharides for stimulating the immune system
US10568896B2 (en) 2013-11-19 2020-02-25 Abbott Laboratories Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
US10639319B2 (en) 2011-08-29 2020-05-05 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
US10709720B2 (en) 2010-12-31 2020-07-14 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
CN112384079A (zh) * 2018-07-12 2021-02-19 N·V·努特里奇亚 用于治疗腹泻的营养组合物、其制备和治疗方法
US11135290B2 (en) 2009-07-15 2021-10-05 N.V. Nutricia Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
US11311562B2 (en) 2010-12-31 2022-04-26 Abbott Laboratories Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
US11446316B2 (en) 2011-07-22 2022-09-20 Abbott Laboratories Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
US11559539B2 (en) 2017-08-11 2023-01-24 N.V. Nutricia Human milk oligosaccharide for improving immune fitness
RU2788854C2 (ru) * 2018-07-12 2023-01-25 Н.В. Нютрисиа Питательная композиция для повышения целостности кишечного барьера, получение композиции и способ лечения

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2465509A1 (de) 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharid Zusammensetzung zur Behandlung von akuten Atemwegsinfektionen
CA2822500C (en) 2010-12-31 2022-07-26 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
WO2012158517A1 (en) * 2011-05-13 2012-11-22 Glycosyn LLC The use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
MX366952B (es) * 2012-03-27 2019-07-31 Abbott Lab Modulación de la inmunidad celular usando oligosacáridos de leche humana.
EP2656862A1 (de) 2012-04-24 2013-10-30 The Procter & Gamble Company Substrat mit einem oder mehr humanen Milcholigosacchariden und Einweg-Aufnahmeartikel mit dem Substrat
ES2572831T3 (es) 2012-09-14 2016-06-02 Abbott Laboratories Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico
US10357506B2 (en) * 2013-11-15 2019-07-23 Nestec S.A. Compositions for use in the prevention or treatment of URT infections in infants or young children at risk
AU2014350146A1 (en) * 2013-11-15 2016-04-07 Nestec S.A. Infant formulas containing a 2-fucosylated oligosaccharide for treatment or prevention of influenza infection
CA3179163A1 (en) * 2014-04-08 2015-10-15 Abbott Laboratories Methods for enhancing mucosal innate immune responses to and/or detection of pathogens using human milk oligosaccharides
US10471084B2 (en) * 2015-03-05 2019-11-12 Glycom A/S Composition and method for treating acute respiratory tract infections
ES2947458T3 (es) 2015-03-05 2023-08-09 Nestle Sa Composiciones para su uso en la prevención o el tratamiento de infecciones gastrointestinales en lactantes o niños pequeños
US20180143186A1 (en) * 2015-05-19 2018-05-24 Nestec S.A. Kit-of-parts to identify mother's milk missing fucosyltransferase-2 dependent glycans and feeding doses with said glycans
CN104940925A (zh) * 2015-07-17 2015-09-30 宁波荣安生物药业有限公司 一种人用狂犬病疫苗及其制备方法
CN107373674A (zh) * 2017-08-25 2017-11-24 西宝生物科技（上海）股份有限公司 一种肿瘤治疗后的营养组合物及其应用
WO2020243371A1 (en) * 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
WO2020239996A1 (en) * 2019-05-29 2020-12-03 N.V. Nutricia Non-digestible oligosaccharides for decreased colonic protein fermentation
SI3883393T1 (sl) * 2019-06-04 2023-01-31 N. V. Nutricia Prehranski sestavek, ki obsega 2'fukozillaktozo in dietetski butirat
CN111011864A (zh) * 2019-12-27 2020-04-17 内蒙古蒙牛乳业（集团）股份有限公司 一种促进肠道健康的营养组分
EP3888661A1 (de) * 2020-03-31 2021-10-06 FrieslandCampina Nederland B.V. Zusammensetzungen mit 2-fucosyllaktose zur verhinderung von virusinfektionen
CN116115623B (zh) * 2022-12-12 2024-02-23 天津市肿瘤医院（天津医科大学肿瘤医院） 2'-岩藻糖基乳糖作为一种抗肿瘤辅助药物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275881A1 (en) * 2003-12-05 2007-11-29 Morrow Ardythe L Oligosaccharide Compositions and Use Thereof in the Treatment of Infection

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002759A (en) * 1989-07-25 1991-03-26 Colgate-Palmolive Company Oligosaccharide inhibition of Streptococcus pyogenes adhesion
US6204431B1 (en) 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
DE19701382A1 (de) * 1997-01-16 1998-07-23 Nutricia Nv Kohlenhydratmischung
US20020019991A1 (en) 1998-04-30 2002-02-14 Abbott Laboratories Compositions containing an alpha 1,2-fucose linkage and uses thereof
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
AU2001231746C1 (en) 2000-03-01 2005-10-06 Societe Des Produits Nestle S.A. Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response
FR2814471B1 (fr) * 2000-09-27 2004-12-17 Centre Nat Rech Scient Utilisation de polymeres et d'oligomeres de xyloglucane, et de composes derives, en tant que produits phytosanitaires et biofertilisants
RU2373769C2 (ru) 2003-10-24 2009-11-27 Н.В. Нютрисиа Синбиотическая композиция для детей
SI1721612T1 (sl) * 2003-10-24 2009-08-31 Nutiricia Nv Imunomodulirajoči oligosaharidi
EP1597978A1 (de) 2004-05-17 2005-11-23 Nutricia N.V. Synergie von GOS und polyfruktose
PL1629850T5 (pl) 2004-08-24 2013-09-30 Nutricia Nv Kompozycja odżywcza zawierająca niestrawne transgalaktooligosacharydy i strawne galaktozosacharydy
CN101123888B (zh) * 2005-02-21 2016-03-23 雀巢技术公司 寡糖混合物
WO2007010084A2 (en) 2005-07-15 2007-01-25 Johannes Savolainen Immunostimulatory oligo- and polysaccharides and uses thereof
EP1776877A1 (de) * 2005-10-21 2007-04-25 N.V. Nutricia Methode zur Förderung der Darmflora
US20090156550A1 (en) 2005-12-06 2009-06-18 Potappel-Van T Land Belinda Composition containing oligosaccharides for the treatment/prevention of infections
CA2645472C (en) * 2006-03-10 2015-09-15 N.V. Nutricia Use of non-digestable saccharides for giving an infant the best start after birth
WO2007114683A1 (en) 2006-03-30 2007-10-11 N.V. Nutricia Milk oligosaccharides for stimulating the immune system
CA2591496C (en) * 2006-12-18 2014-09-02 Japan Science And Technology Agency Method of measuring interaction between biomaterial and sugar chain, method of evaluating biomaterial in sugar chain selectivity, method of screening biomaterial, method of patterning biomaterials, and kits for performing these methods
WO2009067000A1 (en) 2007-11-20 2009-05-28 N.V. Nutricia Composition with synbiotics
EP2072052A1 (de) * 2007-12-17 2009-06-24 Nestec S.A. Verhinderung opportunistischer Infektionen bei Personen mit schwachem Immunsystem
WO2010143940A1 (en) 2009-06-12 2010-12-16 N.V. Nutricia Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta-1,4/1,6 linkages
EP4197542A1 (de) 2009-07-15 2023-06-21 N.V. Nutricia Fucosyllaktose als muttermilchidentisches unverdauliches oligosaccharid zur verwendung bei der verbesserung der impfreaktion
WO2011008086A1 (en) * 2009-07-15 2011-01-20 N.V. Nutricia Mixture of non-digestible oligosaccharides for stimulating the immune system
CN103391783A (zh) 2010-12-31 2013-11-13 雅培制药有限公司 使用人乳寡糖改善呼吸道健康的方法
AU2014350146A1 (en) 2013-11-15 2016-04-07 Nestec S.A. Infant formulas containing a 2-fucosylated oligosaccharide for treatment or prevention of influenza infection
CN105813475A (zh) 2013-12-12 2016-07-27 雀巢产品技术援助有限公司 特别适合于男女婴儿和幼儿的合成营养组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275881A1 (en) * 2003-12-05 2007-11-29 Morrow Ardythe L Oligosaccharide Compositions and Use Thereof in the Treatment of Infection

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
Carver JD. . Advances in nutritional modifications of infant formulasAm J Clin Nutr 2003;77(suppl):1550S-4S. *
Childhood Vaccine Schedule (internet download, published in spring 2008) *
Dog Vaccination Schedule (Internet download, publication date November 29, 2008) *
Grollman, et al. Biosynthesis of Fueosyllactose and Other Oiigosaccharides. THE JOURNAL OF BIOLOGICAL CHEMISTRY. Vol. 240, No. 3, March 1965 *
Hesseling et al. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. INT J TUBERC LUNG DIS. 2008, 12(12):1376-1379. *
Kohlhuber et al. Breastfeeding rates and duration in Germany: a Bavarian cohort study. Br J Nutr. 2008 May;99(5):1127-32. Epub 2008 Feb 25. *
Milk Facts - Nutritional Components in Milk. [online] Retrieved 10/23/2012 from the Internet http://www.milkfacts.info/Nutrition%20Facts/Nutritional%20Components.htm *
OLAV T. OFTEDAL. Lactation in the Dog: Milk Composition andIntake by Puppies. J. Nutr. 114: 803-812, 1984. *
Ruiz-Palacios GM et al. Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem. 2003 Apr 18;278(16):14112-20. *
Sumiyoshi W et al. Determination of each neutral oligosaccharide in the milk of Japanese women during the course of lactation. Br J Nutr. 2003 Jan;89(1):61-9. *
Urashima T, Saito T, Nakamura T, Messer M. Oligosaccharides of milk and colostrum in non-human mammals. Glycoconj J. 2001 May;18(5):357-71. *
Vandenplas Y. Oligosaccharides in infant formula. Br J Nutr. 2002 May;87 Suppl 2:S293-6. *
Zoppi G et al. Diet and antibody response to vaccinations in healthy infants. Lancet. 1983 Jul 2;2(8340):11-4. *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10420784B2 (en) 2009-07-15 2019-09-24 N.V. Nutricia Mixture of non-digestible oligosaccharides for stimulating the immune system
US11135290B2 (en) 2009-07-15 2021-10-05 N.V. Nutricia Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
US11090321B2 (en) 2009-07-15 2021-08-17 N.V. Nutricia Mixture of non-digestible oligosaccharides for stimulating the immune system
US10813940B2 (en) 2010-12-31 2020-10-27 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
US20180133235A1 (en) * 2010-12-31 2018-05-17 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US11701376B2 (en) 2010-12-31 2023-07-18 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
US10973837B2 (en) 2010-12-31 2021-04-13 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US20180161351A1 (en) * 2010-12-31 2018-06-14 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US20180161354A1 (en) * 2010-12-31 2018-06-14 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US20180161352A1 (en) * 2010-12-31 2018-06-14 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US11690859B2 (en) 2010-12-31 2023-07-04 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
US10369164B2 (en) 2010-12-31 2019-08-06 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US9763970B2 (en) 2010-12-31 2017-09-19 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
US10471081B2 (en) 2010-12-31 2019-11-12 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
US11654156B2 (en) 2010-12-31 2023-05-23 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US11633412B2 (en) * 2010-12-31 2023-04-25 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US10709720B2 (en) 2010-12-31 2020-07-14 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
US11524018B2 (en) 2010-12-31 2022-12-13 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US20150031645A1 (en) * 2010-12-31 2015-01-29 Abbott Laboratories Methods of using human milk oligosaccharides for improving airway respiratory health
US20180055864A1 (en) * 2010-12-31 2018-03-01 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US9539269B2 (en) 2010-12-31 2017-01-10 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
US9808474B2 (en) 2010-12-31 2017-11-07 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US11464793B2 (en) 2010-12-31 2022-10-11 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US11311562B2 (en) 2010-12-31 2022-04-26 Abbott Laboratories Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
US11179406B2 (en) 2010-12-31 2021-11-23 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
US11207335B2 (en) * 2010-12-31 2021-12-28 Abbott Laboratories Methods of using human milk oligosaccharides for improving airway respiratory health
US11197875B2 (en) * 2010-12-31 2021-12-14 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US11446316B2 (en) 2011-07-22 2022-09-20 Abbott Laboratories Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
US10639319B2 (en) 2011-08-29 2020-05-05 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
US11135233B2 (en) 2013-11-19 2021-10-05 Abbott Laboratories Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
US10568896B2 (en) 2013-11-19 2020-02-25 Abbott Laboratories Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
US11229658B2 (en) 2015-03-05 2022-01-25 Societe Des Produits Nestle S.A. Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children
WO2016139328A1 (en) * 2015-03-05 2016-09-09 Nestec S.A. Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children
AU2016227595B2 (en) * 2015-03-05 2020-08-27 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children
US11179405B2 (en) * 2016-09-07 2021-11-23 Societe Des Produits Nestle S.A. Nutritional compositions for infants and/or young children comprising oligosaccharides
US20190209593A1 (en) * 2016-09-07 2019-07-11 Nestec S.A. Nutritional compositions for infants and/or young children comprising oligosaccharides
US11559539B2 (en) 2017-08-11 2023-01-24 N.V. Nutricia Human milk oligosaccharide for improving immune fitness
RU2788854C2 (ru) * 2018-07-12 2023-01-25 Н.В. Нютрисиа Питательная композиция для повышения целостности кишечного барьера, получение композиции и способ лечения
CN112384079A (zh) * 2018-07-12 2021-02-19 N·V·努特里奇亚 用于治疗腹泻的营养组合物、其制备和治疗方法

Also Published As

Publication number Publication date
RU2530641C2 (ru) 2014-10-10
US20180264104A1 (en) 2018-09-20
US20160158346A1 (en) 2016-06-09
US10588965B2 (en) 2020-03-17
BR112012000859B1 (pt) 2021-08-03
CN102497869A (zh) 2012-06-13
BR112012000859A2 (pt) 2018-03-13
WO2011008087A1 (en) 2011-01-20
PL3342413T3 (pl) 2022-03-28
EP4197542A1 (de) 2023-06-21
US11135290B2 (en) 2021-10-05
PL2453901T3 (pl) 2015-03-31
MY195771A (en) 2023-02-10
EP3342413B1 (de) 2021-10-20
EP3342413A1 (de) 2018-07-04
US20220023418A1 (en) 2022-01-27
CN102497869B (zh) 2013-11-27
ES2525565T3 (es) 2014-12-26
ES2904608T3 (es) 2022-04-05
EP2813230A1 (de) 2014-12-17
EP2453901B1 (de) 2014-09-10
RU2012105310A (ru) 2013-08-20
US20200155672A1 (en) 2020-05-21
MY164674A (en) 2018-01-30
EP2453901A1 (de) 2012-05-23

Similar Documents

Publication Publication Date Title
US11135290B2 (en) Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
US11090321B2 (en) Mixture of non-digestible oligosaccharides for stimulating the immune system
JP4965444B2 (ja) 免疫刺激性乳児用栄養
TW201438719A (zh) 改善壓力症狀之母乳寡糖
TW201233335A (en) Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin C and anti-inflammatory agents
EP1957084B1 (de) Zusammensetzung mit oligosacchariden zur behandlung/prävention von fieber und fieberanfällen
US11559539B2 (en) Human milk oligosaccharide for improving immune fitness
EP2563165A1 (de) Verwendung von 6'-sialyllactose für baby- und kleinkindernahrung
WO2011136636A1 (en) Use of 6'-sialyl lactose in infant nutrition
BR122021007429B1 (pt) Uso de 2'-fucosilactose na fabricação de uma composição enteral
CA3198961A1 (en) Synthetic compositions comprising lnfp iii and lsta
WO2012044155A1 (en) Fat composition for programming immune response

Legal Events

Date Code Title Description
AS Assignment

Owner name: N.V. NUTRICIA, NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STAHL, BERND;NAUTA, ALMA JILDOU;GARSSEN, JOHAN;AND OTHERS;REEL/FRAME:027999/0363

Effective date: 20120305

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION